IDEAYA Biosciences, Inc.
$33.6
▲
0.8%
2026-04-21 07:27:01
www.ideayabio.com
NMS: IDYA
Explore IDEAYA Biosciences, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2.95 B
Current Price
$33.6
52W High / Low
$39.28 / $16.07
Stock P/E
—
Book Value
$11.65
Dividend Yield
—
ROCE
-15.17%
ROE
-10.92%
Face Value
—
EPS
$-1.28
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
145
Beta
0.02
Debt / Equity
2.73
Current Ratio
11.34
Quick Ratio
11.34
Forward P/E
-9.05
Price / Sales
12.25
Enterprise Value
$2.07 B
EV / EBITDA
-13.2
EV / Revenue
9.45
Rating
Strong Buy
Target Price
$50
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Maravai LifeSciences Holdings, Inc. | $3.61 | — | $928.01 M | — | -17.71% | -48.59% | $4.11 / $1.67 | $1.46 |
| 2. | Phathom Pharmaceuticals, Inc. | $13.47 | — | $1.04 B | — | -125.87% | 63.97% | $18.31 / $2.21 | $-6.13 |
| 3. | Nurix Therapeutics, Inc. | $17.04 | — | $1.81 B | — | -47.48% | -61.4% | $22.5 / $8.2 | $4.65 |
| 4. | Ascentage Pharma Group Internat | $25.65 | — | $18.58 B | — | -25.48% | -1.55% | $95.35 / $36.5 | $0.52 |
| 5. | Rocket Pharmaceuticals, Inc. | $3.86 | — | $421.21 M | — | -76.11% | -60.27% | $8.26 / $2.19 | $2.56 |
| 6. | Aprea Therapeutics, Inc. | $0.98 | — | $11.45 M | — | -100.49% | -74.58% | $2.22 / $0.55 | $1.52 |
| 7. | Precigen, Inc. | $4.11 | — | $1.45 B | — | -90.19% | -5.72% | $5.46 / $1.23 | $0.06 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 10.88 M | 207.83 M | 0 M | 0 M | 7 M |
| Operating Profit | -94.57 M | 108.45 M | -88.81 M | -84.39 M | -144.14 M |
| Net Profit | -83.27 M | 119.24 M | -77.49 M | -71.41 M | -130.31 M |
| EPS in Rs | -0.95 | 1.36 | -0.88 | -0.81 | -1.48 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 218.71 M | 7 M | 23.39 M | 50.93 M |
| Operating Profit | -159.31 M | -326.98 M | -134.43 M | -62.5 M |
| Net Profit | -113.7 M | -274.48 M | -112.96 M | -58.66 M |
| EPS in Rs | -1.29 | -3.13 | -1.29 | -0.67 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.11 B | 1.12 B | 649.32 M | 387.97 M |
| Total Liabilities | 86.39 M | 64.94 M | 28.23 M | 38.51 M |
| Equity | 1.02 B | 1.06 B | 621.09 M | 349.45 M |
| Current Assets | 666.73 M | 689.71 M | 532.63 M | 370.45 M |
| Current Liabilities | 58.81 M | 46.07 M | 27.1 M | 31.72 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -71.1 M | -247.58 M | -115.22 M | -87.17 M |
| Investing CF | 69.98 M | -502.56 M | -158.46 M | -33.4 M |
| Financing CF | 29.78 M | 677.55 M | 362.72 M | 97.17 M |
| Free CF | -73.47 M | -251.44 M | -117.59 M | -90.62 M |
| Capex | -2.37 M | -3.86 M | -2.37 M | -3.44 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -70.07% | -54.08% | — | — |
| Earnings Growth % | -142.98% | -92.59% | — | — |
| Profit Margin % | -3921.1% | -483.05% | -115.17% | — |
| Operating Margin % | -4671.07% | -574.85% | -122.72% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -4616.3% | -557.71% | -115.82% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.